Cardiff Oncology posts updated corporate presentation on onvansertib clinical pipeline

Cardiff Oncology, Inc.

Presentation covers onvansertib as a PLK1 inhibitor with potential in KRAS-mutated cancers.
Highlights ongoing Phase 1b/2 trials in mCRC, mPDAC, TNBC, and SCLC with historical ORR benchmarks.
Includes strategic goals for 2022-2025: demonstration, confirmation, and positioning for registration.
No specific new clinical data or financial guidance announced in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.